Does Rallies show 13F holders for TMCI?

Yes. Rallies tracks hedge fund and 13F ownership data for TMCI, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TMCI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TMCI. It does not provide personalized investment advice.

TMCI (Treace Medical Concepts, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Treace Medical Concepts, Inc. Common Stock (TMCI) is a publicly traded Healthcare sector company. As of May 21, 2026, TMCI trades at $2.82 with a market cap of $178.40M and a P/E ratio of -2.93. TMCI moved +3.31% today. Year to date, TMCI is +6.82%; over the trailing twelve months it is -57.85%. Its 52-week range spans $1.17 to $10.79. Analyst consensus is neutral with an average price target of $3.56. Rallies surfaces TMCI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TMCI stock?

Hedge funds tracked by Rallies that own TMCI include Centerbook Partners, Bridgewater Associates, and Pinebridge Investments. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Treace Medical Concepts, Inc. Common Stock.

TMCI Key Metrics

Key financial metrics for TMCI
Metric	Value
Price	$2.82
Market Cap	$178.40M
P/E Ratio	-2.93
EPS	$-0.96
Dividend Yield	0.00%
52-Week High	$10.79
52-Week Low	$1.17
Volume	0
Avg Volume	0
Revenue (TTM)	$207.32M
Net Income	$-61.04M
Gross Margin	79.72%

Top Hedge Funds Holding TMCI

Centerbook Partners holds 674.37K shares of TMCI, changed +19.84% as of Sep 30, 2025.
Bridgewater Associates holds 36.70K shares of TMCI, changed +9.48% as of Mar 31, 2024.
Pinebridge Investments holds 1.31K shares of TMCI, changed +0.00% as of Jun 30, 2023.

Latest TMCI News

Treace Maintains 2026 Revenue Outlook Despite Q1 Sales Decline — May 9, 2026
Shares Rise 4.47% After Treace Medical Q1 Revenue $47.2M, EPS Loss –$0.28 — May 8, 2026
Treace Medical Posts 10% Drop to $47.2M Q1 Revenue and Launches SuperBite System — May 8, 2026
Treace Debuts SuperBite Screws with 2.5–7.0mm Range, Targets $300M Market Growth — Apr 7, 2026
Treace Medical Reports $9.4M Q4 Loss, Guides $200M–$212M 2026 Revenue — Feb 27, 2026

Recent TMCI Insider Trades

Treace John T. bought 61.75K (~$161.49K) on May 14, 2026.
Treace John T. bought 49.01K (~$120.53K) on May 13, 2026.
Treace John T. bought 43.00K (~$93.48K) on May 12, 2026.

TMCI Analyst Consensus

4 analysts cover TMCI: 0 strong buy, 1 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $3.56.

Common questions about TMCI

Who owns TMCI stock?: Hedge funds tracked by Rallies that own TMCI include Centerbook Partners, Bridgewater Associates, and Pinebridge Investments. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Treace Medical Concepts, Inc. Common Stock.
Does Rallies show 13F holders for TMCI?: Yes. Rallies tracks hedge fund and 13F ownership data for TMCI, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TMCI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TMCI. It does not provide personalized investment advice.